Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 21, 2022 Category: Cancer & Oncology Source Type: research
Chemotherapy in pancreatic ductal adenocarcinoma: when cytoreduction is the aim. A systematic review and meta-analysis
According to GLOBOCAN 2020, pancreatic cancer is currently the 7th most common fatal cancer worldwide [1]. However, in some regions as Europe and North America, it represents the 4th most common cause of cancer death [2,3]. Pancreatic adenocarcinoma (PDAC) accounts for 80% of all pancreatic cancers. [4] It is a neoplasm with poor prognosis, even for early stages. The 5-year relative survival is 41.5% for patients with localized disease, 14.4% for regional disease and 3% for those with metastatic disease [5 –7]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 21, 2022 Category: Cancer & Oncology Authors: Monica I. Meneses-Medina, Lorenzo Gervaso, Chiara A. Cella, Stefania Pellicori, Sara Gandini, Maria J. Sousa, Nicola Fazio Source Type: research
Global challenges and policy solutions in breast cancer control
Breast cancer is a leading cause of morbidity, disability and mortality in women, worldwide.[1] In 2020, breast cancer became the most diagnosed malignancy overall, surpassing lung cancer for the first time in history. It is also a major cause of death from cancer among women, accounting for 15.5% of cancer-related deaths. Breast cancer is the most prevalent malignancy with more than 7.7 million women living five years from diagnosis.[2] Data from population-based registries show that the survival at 5 years after a diagnosis of breast cancer exceeds 90% in high-income countries but is considerably lower in many low- and m...
Source: Cancer Treatment Reviews - January 18, 2022 Category: Cancer & Oncology Authors: Dario Trapani, Ophira Ginsburg, Temidayo Fadelu, Nancy U. Lin, Michael Hassett, Andre M. Ilbawi, Benjamin O. Anderson, Giuseppe Curigliano Source Type: research
Acknowledgement to Reviewers 2021
The Editors would like to thank the reviewers listed below who do such excellent work for Cancer Treatment Reviews. Without their knowledge, skill and dedication the journal would not achieve the high standard of peer review that we seek to maintain at all times. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 13, 2022 Category: Cancer & Oncology Source Type: research
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology
It is estimated that ∼5-10% of all cancers are due to pathogenic variants (PV) inherited in the germline.[1] For high-risk families, early identification of a cancer-predisposing germline PV is critical, as subsequent genetic counseling can encourage and motivate patients to adhere to risk-reducing interventions.[1] G ermline PVs in DNA repair genes are known to not only increase cancer risk but are also relevant for guiding cancer treatment. DNA repair is crucial for genome stability, with multiple specialized pathways existing in the cell to repair different types of DNA lesions (Figure 1). (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 5, 2022 Category: Cancer & Oncology Authors: Shreya M. Shah, Elena V. Demidova, Randy W. Lesh, Michael J. Hall, Mary B. Daly, Joshua E. Meyer, Martin J. Edelman, Sanjeevani Arora Source Type: research
How Far We Have Come Targeting BRAF-Mutant Non-Small Cell Lung Cancer (NSCLC)
BRAF belongs to the RAF family of serine/threonine kinases, which also includes ARAF and CRAF. RAF kinases are key players in the MAPK signaling pathway, which regulates cell proliferation, differentiation and survival (Figure 1). Almost two decades after the first report on cancer driver mutations in the BRAF kinase domain [1], nearly 300 distinct BRAF mutations have been identified in tumor samples and cancer cell lines from melanoma, colorectal cancer, papillary thyroid cancer and non-small cell lung cancer (NSCLC) [2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 31, 2021 Category: Cancer & Oncology Authors: Fabrizio Tabb ò, Chiara Pisano, Julien Mazieres, Laura Mezquita, Ernest Nadal, David Planchard, Anne Pradines, David Santamaria, Aurélie Swalduz, Chiara Ambrogio, Silvia Novello, Sandra Ortiz-Cuaran, on behalf of the BOLERO Consortium Source Type: research
Clinical development of IDH1 inhibitors for cancer therapy
Since the validation of targeted cancer therapies in the late 1990s, numerous active agents have been developed against a variety of different cancer types. Rituximab and trastuzumab were among the first examples, which proved to be highly effective against B-cell lymphoma and HER2-positive breast cancer, respectively [1,2]. In the last seven years alone, 83 drugs aimed at 56 different targets have been approved by the United States Food& Drug Administration (FDA) for the treatment of solid and hematologic malignancies [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 28, 2021 Category: Cancer & Oncology Authors: Mehrdad Zarei, Jonathan J. Hue, Omid Hajihassani, Hallie J. Graor, Erryk S. Katayama, Alexander W. Loftus, David Bajor, Luke D. Rothermel, Ali Vaziri-Gohar, Jordan M. Winter Source Type: research
Management of Adverse Events Associated with Cabozantinib Plus Nivolumab in Renal Cell Carcinoma: A Review
Treatment of advanced clear-cell renal cell carcinoma (RCC) has improved in recent years with the introduction of novel tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs [PD-L1, PD-1, and CTLA-4 inhibitors]) [1 –3]. Due to the angiogenic nature of RCC, TKIs targeting the vascular endothelial growth factor receptor (VEGFR) have been a cornerstone of therapy, providing improved disease control and survival with manageable safety profiles [4,5]. RCC is also immunogenic [4], which led to the development of I CIs in RCC as single-agents, in dual ICI combinations, and in combination with TKIs that have i...
Source: Cancer Treatment Reviews - December 23, 2021 Category: Cancer & Oncology Authors: Bradley McGregor, Amir Mortazavi, Lisa Cordes, Cristina Salabao, Susan Vandlik, Andrea B. Apolo Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 22, 2021 Category: Cancer & Oncology Source Type: research
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: an individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature
Colorectal cancer (CRC) is one of the most frequent malignancies, representing the second leading overall cause of cancer death [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 22, 2021 Category: Cancer & Oncology Authors: Pasquale Lombardi, Daniele Rossini, Veronica Crespi, Marco Maria Germani, Francesca Bergamo, Filippo Pietrantonio, Daniele Santini, Giacomo Allegrini, Francesca Daniel, Filippo Pagani, Carlotta Antoniotti, Alberto Zaniboni, Veronica Conca, Tiziana Pia Lat Source Type: research
A comprehensive overview of tumour deposits in colorectal cancer: towards a next TNM classification
Colorectal cancer (CRC) is currently the third most common cancer worldwide and the second leading cause of cancer deaths, with more than 1,800,000 new cases and nearly 900,000 deaths each year, worldwide [1]. Its management is based on the TNM staging system, developed in the 1950s, which has been constantly evolving throughout the history of scientific advances [2-6]. The latest 8th edition of the TNM classification has been published in 2017 [7]. Yet, it is essential to identify new histological markers to further improve the classification and to define more relevant subgroups of patients. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 20, 2021 Category: Cancer & Oncology Authors: Jean-Fran çois Delattre, Ayse Selcen Oguz Erdogan, Romain Cohen, Qian Shi, Jean-François Emile, Julien Taieb, Josep Tabernero, Thierry André, Jeffrey A. Meyerhardt, Iris D. Nagtegaal, Magali Svrcek Source Type: research
Targeting brain metastases in breast cancer
Metastatic breast cancer (BC) is, after lung cancer, the second most common cancer associated with brain metastases (BMs) [1]. As cancer research breakthroughs considerably improved survival of patients with advanced stage BC in the last decades, the incidence of BMs is increasing accordingly [2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 16, 2021 Category: Cancer & Oncology Authors: Chiara Corti, Gabriele Antonarelli, Carmen Criscitiello, Nancy U. Lin, Lisa A. Carey, Javier Cort és, Philip Poortmans, Giuseppe Curigliano Source Type: research
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2 − breast cancer: Available evidence and clinical implications
Initially implemented in clinical practice for the treatment of locally advanced breast cancer (BC) patients, the use of neoadjuvant treatment has progressively increased over the last decades and is nowadays considered the standard of care for many early BC patients as well [1,2]. In this context, neoadjuvant chemotherapy (NCT) is widely used to downstage initially operable BCs, increasing the rates of conservative surgery [3]; however, it is well-known that the magnitude of response to NCT varies significantly according to breast cancer subtype. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 2, 2021 Category: Cancer & Oncology Authors: Gaia Griguolo, Michele Bottosso, Grazia Vernaci, Federica Miglietta, Maria Vittoria Dieci, Valentina Guarneri Tags: Hot Topic Source Type: research
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available Evidence and Clinical Implications
Initially implemented in clinical practice for the treatment of locally advanced breast cancer (BC) patients, the use of neoadjuvant treatment has progressively increased over the last decades and is nowadays considered the standard of care for many early BC patients as well [1,2]. In this context, neoadjuvant chemotherapy (NCT) is widely used to downstage initially operable BCs, increasing the rates of conservative surgery[3]; however, it is well-known that the magnitude of response to NCT varies significantly according to breast cancer subtype. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 2, 2021 Category: Cancer & Oncology Authors: Gaia Griguolo, Michele Bottosso, Grazia Vernaci, Federica Miglietta, Maria Vittoria Dieci, Valentina Guarneri Source Type: research
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities
A deepening of understanding the molecular pathways of tumor progression have been the basic requirements for the development of so-called targeted therapies and ICIs. This new generation of drugs is designed to specifically block tumor cell proliferation, angiogenesis or immune escape mechanisms and intend to reduce high cytotoxicity associated with chemotherapy. On the one hand, much attention has been devoted to the notion that a growing tumor requires blood supply and allowed the development of monoclonal antibodies and small molecule inhibitors directed against angiopoietin-2 (Ang-2), vascular endothelial growth facto...
Source: Cancer Treatment Reviews - November 30, 2021 Category: Cancer & Oncology Authors: Alexander T. Bauer, Christian Gorzelanny, Christoffer Gebhardt, Klaus Pantel, Stefan W. Schneider Source Type: research
